查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715645

鼻腔藥物和疫苗傳輸市場（按藥物類型、劑型、設備類型、劑量、應用和最終用戶分類）—2025 年至 2030 年全球預測

Intranasal Drug & Vaccine Delivery Market by Drug Type, Formulation Type, Device Type, Dosage, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年鼻腔內藥物和疫苗輸送市場價值為 469.8 億美元，預計 2024 年將成長至 495.9 億美元，複合年成長率為 5.88%，預計到 2030 年將達到 701.2 億美元。

主要市場統計數據
基準年2023年 469.8億美元
預計2024年 495.9億美元
預測年份 2030 701.2億美元
複合年成長率（%） 5.88%

鼻腔給藥和疫苗輸送是製藥領域的重要進步，為傳統給藥途徑提供了一種有效、非侵入性的替代方法。本介紹深入探討了一個快速發展的市場，其特點是創新研究、技術突破和監管支持不斷增加。隨著研究人員、製造商和醫療保健專業人員不斷探索最佳化治療結果和提高患者依從性的方法，鼻腔給藥因其吸收迅速、給藥方便以及可直接進入全身和局部治療途徑的潛力而成為領先者。

這一領域的發展受到令人信服的臨床數據和以患者為中心的研究的推動，這些研究表明，鼻內給藥不僅可以增強吸收，還可以繞過主要的代謝障礙。因此，人們越來越重視在藥物和疫苗方面利用這種方法。這份全面的概述探討了當前市場動態的細微差別、產品設計和交付的技術創新以及重塑鼻內治療格局的戰略因素。隨著此類輸送系統的開發和應用勢頭強勁，它們有望徹底改變治療幾個主要治療領域的藥理學方法，包括疼痛、荷爾蒙失調、感染疾病和神經系統疾病。

隨著市場認知到簡化給藥機制的重要性，鼻腔給藥途徑的採用正引起多方相關人員的興趣。廣泛的分析表明，其多面性正在導致對配方研究、設備創新和臨床試驗的大量投資。提供安全、有效和方便用戶使用的藥物輸送選擇的緊迫性仍然是正在進行的研究的重點，本報告力求清晰、準確地捕捉此類突破的本質。

重塑鼻腔給藥​​格局的變革

近年來，發生了一些變革，重新定義了鼻內藥物和疫苗傳遞的模式。隨著研究的加速和革命性技術整合的出現，該行業正在經歷模式轉移，引起了全球相關人員的關注。政府關注度的提高和支持性監管政策為加速藥品核准和創新試驗設計鋪平了道路。

從微流體噴霧器到精密設計的滴管，最尖端科技的引入凸顯了鼻內給藥系統成功發展的趨勢。製造商正在大力投資產品開發工作，以確保最佳化的配方與尖端的輸送裝置相匹配，從而確保最大的治療效果，同時最大限度地減少副作用。配方科學和設備技術交叉領域的專注努力帶來了顯著提高藥物生物生物有效性的創新。此外，隨著急性和預防性醫療干預中對快速起效的要求變得越來越重要，這些新型給藥系統的功效正在臨床界和患者群體的認可和接受。

隨著我們對鼻腔生理學及其作為中樞神經系統輸送通道的潛力的理解不斷加深，產業領導者不僅投資於研發，而且還積極尋求策略聯盟。這些夥伴關係正在加快創新步伐，創造一個可以在創紀錄的時間內測試和改進新藥和疫苗候選物的環境。這種轉變由下一代鼻內製劑的強大管道進一步證明，這些製劑有望提高患者的依從性、改善安全性並擴大多種健康狀況的治療用途。簡而言之，這些動態轉變正在重新定義市場預期，並為整個產業建立強大的、面向未來的基礎。

闡明市場結構的關鍵細分洞察

對鼻腔給藥市場進行詳細細分，可以發現其複雜的層次，這些層次對其整體廣度和深度做出了重大貢獻，說明了該行業的複雜性和動態性。基於藥物類型的市場分析深入研究了止痛藥、抗組織胺藥物、類固醇、疫苗等應用。在此框架內，進一步檢視止痛藥以區分非鴉片類藥物和鴉片類藥物，並將疫苗明確分為去活化疫苗、減毒活病毒疫苗和基於 mRNA 的疫苗。這種詳細的細分強調了多樣化配方策略的必要性，並強調了不同治療背景下不斷變化的需求。

除此之外，市場還根據配方類型進行細分，重點關注凝膠、液體和粉末配方。這種分類反映了鼻腔製劑的物理特性和穩定性要求的多樣性，最終影響製造過程和患者的可用性。同時，調查設備的類型也很重要，我們的分析重點是霧化器、滴鼻器和鼻噴霧等設備。每個設備在確保正確的劑量達到預期目標、最大限度地提高治療效果和最大限度地減少藥物輸送的變化方面發揮關鍵作用。

此外，基於劑量的細分突出了多劑量產品和單位劑量產品之間的二分法。這種細分方面揭示了確保劑量精確度和最佳化不同臨床場景的傳輸機制所需的操作挑戰和技術創新。此外，按應用細分市場可以揭示廣泛的治療領域，包括過敏治療、荷爾蒙替代、神經系統疾病、疼痛管理、精神疾病和藥物傳輸治療。對這些不同應用的認知突顯瞭如何客製化鼻內給藥以滿足特定的臨床需求。

此外，基於最終用戶屬性的細分包括居家醫療、醫院/診所和研究/學術機構等設置。這方面體現了以患者為中心的開發和研發的重視，並強調了鼻內給藥的廣泛效用。這些市場細分洞察揭示了一個多層次的市場，每個細分市場都對整體成長軌跡做出了獨特的貢獻，突顯了專業化的機會和成熟的創新領域。對於希望有效指導研發投資和策略規劃的相關人員來說，了解這些細微的差別至關重要。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 感染疾病的流行和對注射器相關感染的日益擔憂正在推動鼻內給藥系統的發展。
      • 自行用藥和非侵入性給藥途徑的日益普及
      • 擴大專注於經鼻吸入型疫苗創新的研發活動
    • 限制因素
      • 替代藥物傳遞方法的可用性和產品召回的潛在風險
    • 機會
      • 鼻內給藥系統的進展
      • 大力投資鼻腔給藥及疫苗輸送創新研發
    • 任務
      • 與鼻腔內給藥相關的潛在不良反應和副作用
  • 市場區隔分析
    • 藥物類型：非鴉片類止痛藥用於治療慢性疼痛和長期使用的情況正在增加，因為它們成癮和副作用的風險較低。
    • 配方類型：鼻腔藥物和疫苗傳遞的創新解決方案和新興應用
    • 設備類型：急救護理的準確性和有效性推動了對霧化器的需求
    • 劑量：由於成本效益和材料效率，多劑量形式越來越受到大規模疫苗接種計畫和慢性治療通訊協定的青睞。
    • 應用：在治療過敏症時，越來越多人選擇透過鼻腔給藥和疫苗給藥來注射皮質類固醇和抗組織胺藥
    • 最終用戶：便利性和隱私性的提高將推動居家照護環境中更多地採用鼻腔給藥和疫苗給藥
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 鼻腔給藥及疫苗給藥市場（依藥物類型）

  • 止痛藥
    • 非鴉片類藥物
    • 鴉片類藥物
  • 抗組織胺藥
  • 類固醇
  • 疫苗
    • 去活化疫苗
    • 減毒活疫苗
    • 基於mRNA的疫苗

7. 鼻腔給藥及疫苗遞送市場（按劑型）

  • 凝膠配方
  • 液體製劑
  • 粉末製劑

8. 鼻腔給藥及疫苗輸送市場（依設備類型）

  • 霧化器
  • 滴鼻器
  • 鼻噴劑

9. 鼻腔給藥和疫苗給藥市場（按劑量）

  • 多劑量
  • 單位劑量

第10章 鼻腔給藥與疫苗輸送市場（依應用）

  • 過敏治療
  • 荷爾蒙補充療法
  • 神經系統疾病
  • 疼痛管理
  • 精神疾病
  • 治療藥物輸送

第 11 章。鼻腔藥物和疫苗傳輸市場（按最終用戶分類）

  • 居家護理
  • 醫院和診所
  • 研究和學術機構

12.美洲鼻腔藥物和疫苗傳輸市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區鼻腔藥物和疫苗傳輸市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14. 歐洲、中東和非洲鼻腔藥物和疫苗傳輸市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Altimmune, Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Becton, Dickinson, and Company
  • Bharat Biotech Ltd.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • DCA Design International Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Hovione Limited
  • Impel Pharmaceuticals LLC.
  • Indivior PLC
  • Intersect ENT by Medtronic plc
  • Intertek Group PLC
  • Johnson & Johnson Services, Inc.
  • Kindeva Drug Delivery LP
  • Merck & Co., Inc.
  • Neurelis, Inc.
  • Novartis AG
  • OptiNose, Inc.
  • Pfizer Inc.
  • Recipharm AB.
  • Sanofi SA
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A339DAEFA961

The Intranasal Drug & Vaccine Delivery Market was valued at USD 46.98 billion in 2023 and is projected to grow to USD 49.59 billion in 2024, with a CAGR of 5.88%, reaching USD 70.12 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 46.98 billion
Estimated Year [2024] USD 49.59 billion
Forecast Year [2030] USD 70.12 billion
CAGR (%) 5.88%

Intranasal drug and vaccine delivery represents a significant advancement in the field of pharmaceuticals, offering an effective and non-invasive alternative to traditional routes of administration. This introduction sets the stage for an in-depth exploration of a rapidly evolving market characterized by innovative research, technological breakthroughs, and increasing regulatory support. As researchers, manufacturers, and healthcare professionals continually seek methods to optimize therapeutic outcomes and enhance patient compliance, intranasal delivery is emerging as a front-runner due to its potential for rapid absorption, ease of administration, and direct access to both systemic and localized treatment pathways.

The evolution of this niche sector has been driven by compelling clinical data and patient-centric studies, revealing that the nasal route not only accelerates absorption but also bypasses major metabolic barriers. Consequently, there is a growing emphasis on leveraging this method for both drugs and vaccines. This comprehensive overview will explore the nuances of the current market dynamics, the technological innovations in product design and delivery, and the strategic factors that are reshaping the landscape of intranasal therapy. As the development and application of these delivery systems gain momentum, they promise to transform the pharmacological approach to managing several major therapeutic areas, including pain, hormonal deficits, infectious diseases, and neurological disorders.

As the market acknowledges the importance of streamlined delivery mechanisms, the adoption of intranasal routes is drawing interest from a diverse spectrum of stakeholders. Insights drawn from extensive analysis demonstrate that the multifaceted nature has led to significant investments in formulation research, device innovations, and clinical trials. The urgency to provide safe, efficient, and user-friendly medication delivery options remains at the forefront of ongoing research, and this report endeavors to capture the essence of such breakthroughs with clarity and precision.

Transformative Shifts Reshaping the Intranasal Delivery Landscape

Over recent years, transformative shifts have redefined the framework within which intranasal drug and vaccine delivery operates. Marked by accelerated research and revolutionary technological integration, the industry is experiencing a paradigm shift that has captured the attention of global stakeholders. Increased governmental focus and supportive regulatory policies have paved the way for expedited drug approvals and innovative trial designs, thereby allowing novel products to reach the market faster than ever before.

The infusion of cutting-edge technologies, ranging from microfluidic atomizers to precision-engineered droppers, highlights the progressive trends that underpin the success of intranasal delivery systems. Manufacturers are investing substantially in product development efforts to ensure that optimized formulations are matched with state-of-the-art delivery devices, ensuring maximum therapeutic efficacy while minimizing adverse effects. This concerted focus on marrying formulation science with device technology has led to innovations that significantly improve drug bioavailability. Moreover, as the demand for rapid onset of action becomes increasingly critical in emergency treatments and preventive healthcare interventions, the efficacy of these novel delivery systems is being recognized and embraced by both the clinical community and patient populations.

Catalyzed by a growing understanding of nasal physiology and its potential as a gateway to central nervous system delivery, industry leaders are not only investing in research and development but are also actively engaging in strategic collaborations. Such partnerships are accelerating the pace of innovation and fostering an environment where novel drug and vaccine candidates can be tested and refined in record time. The transformation is further evidenced by the strong pipeline of next-generation intranasal products that promise enhanced patient compliance, improved safety profiles, and expanded therapeutic applications across numerous health conditions. In essence, these dynamic shifts are redefining market expectations and establishing a robust, future-oriented foundation for the entire industry.

Critical Segmentation Insights Illuminating Market Structure

A meticulous segmentation of the intranasal delivery market reveals intricate layers that contribute significantly to its overall breadth and depth, illustrating the complexity and dynamic nature of the field. Market analysis based on drug type delves into applications ranging from analgesics, antihistamines, steroids, and vaccines. Within this framework, analgesics are further scrutinized to differentiate between non-opioids and opioids, while vaccines are distinctly categorized into inactivated vaccines, live attenuated vaccines, and mRNA-based vaccines. This detailed segmentation underscores the need for varied formulation strategies and underscores the evolving requirements across different therapeutic contexts.

In parallel, the market is also segmented based on formulation type, where the focus is on gel, liquid, and powder formulations. This classification reflects the diversity in the physical characteristics and stability requirements of intranasal formulations, ultimately influencing both manufacturing processes and patient usability. Concurrently, the investigation into device type is crucial, with the analysis highlighting instruments such as atomizers, nasal droppers, and nasal sprays. Each device plays a critical role in ensuring that the right dose reaches its intended target, thereby maximizing therapeutic benefits and minimizing variability in drug delivery.

Additionally, segmentation based on dosage focuses on the dichotomy between multi-dose and unit-dose products. This aspect of segmentation sheds light on the operational challenges and technological innovations required to ensure accuracy in dosing and to optimize the delivery mechanism for various clinical scenarios. Furthermore, when the market is segmented by application, the insights extend to a wide array of therapeutic areas including allergy treatment, hormone replacement, neurological conditions, pain management, psychiatric disorders, and therapeutic drug delivery. The recognition of these diversified applications accentuates how intranasal delivery is being tailored to meet specialized clinical needs.

Moreover, segmentation based on end-user demographics includes settings such as homecare, hospitals and clinics, and research and academic institutions. This aspect signals the dual emphasis on both patient-centric and research-focused developments, emphasizing the broad utility of intranasal administration. Together, these segmentation insights reveal a layered market where each segment contributes uniquely to the overall growth trajectory, highlighting both opportunities for specialization and areas ripe for innovation. Understanding these nuanced segments is imperative for stakeholders looking to target their R&D investments and strategic planning effectively.

Based on Drug Type, market is studied across Analgesics, Antihistamines, Steroids, and Vaccines. The Analgesics is further studied across Non-opioids and Opioids. The Vaccines is further studied across Inactivated Vaccines, Live Attenuated Vaccines, and mRNA-based Vaccine.

Based on Formulation Type, market is studied across Gel Formulations, Liquid Formulations, and Powder Formulations.

Based on Device Type, market is studied across Atomizer, Nasal Dropper, and Nasal Spray.

Based on Dosage, market is studied across Multi-dose and Unit-dose.

Based on Application, market is studied across Allergy Treatment, Hormone Replacement, Neurological Conditions, Pain Management, Psychiatric Disorders, and Therapeutic Drug Delivery.

Based on End-User, market is studied across Homecare, Hospitals & Clinics, and Research & Academic Institution.

Detailed Regional Perspectives on Intranasal Delivery Innovations

A regional analysis of the intranasal drug and vaccine delivery market sheds light on diverse geopolitical trends and regional dynamics that are driving growth and innovation across the globe. In the Americas, robust healthcare infrastructure, substantial government funding, and a high rate of technology adoption foster an environment where novel intranasal products are swiftly integrated within existing clinical frameworks. These factors, combined with aggressive investments in research and development, have positioned the region as a leading market for next-generation therapies.

The Europe, Middle East & Africa region presents a contrasting yet equally compelling landscape. The region benefits from mature regulatory systems and an increasing emphasis on personalized healthcare solutions. Government initiatives and collaborative ventures among research institutions and private players are bolstering the development of advanced intranasal delivery systems. This convergence of resources and expertise underlines the region's commitment to addressing complex therapeutic challenges. Although regulatory environments may vary, the collective focus on innovation is driving a notable shift towards products that cater to both acute and chronic medical needs.

Turning attention to the Asia-Pacific region, the market dynamics are primarily characterized by rapid urbanization, rising healthcare awareness, and expanding consumer access to modern medical technologies. Emerging economies in this region are witnessing significant improvements in healthcare delivery systems, facilitated by government reforms and increased investments in R&D infrastructure. The potential to integrate intranasal delivery into large-scale public health initiatives, particularly in the context of vaccination programs, is further accelerating market penetration. This broad regional disparity in economic growth, healthcare policies, and technology adoption ultimately illustrates the varied and rich tapestry of regional market behaviors, each contributing uniquely to the upward growth trajectory of intranasal delivery innovations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

In-Depth Insights into Leading Companies and Competitive Positioning

A detailed competitive analysis of the intranasal drug and vaccine delivery market underscores the significant presence of several key industry players whose innovations and strategic initiatives are instrumental in shaping the future of the therapeutic landscape. Renowned entities such as Altimmune, Inc. and AptarGroup, Inc. are at the forefront of pioneering new formulations and delivery technologies. Major pharmaceutical organizations like AstraZeneca PLC, Bausch Health Companies Inc., and Bayer AG have consistently invested in research to optimize product performance and enhance patient outcomes. Likewise, companies with comprehensive portfolios, such as Becton, Dickinson, and Company, along with Bharat Biotech Ltd. and Boehringer Ingelheim International GmbH, are driving multifaceted initiatives that marry clinical efficacy with technological innovation.

Other prominent participants such as Catalent, Inc and DCA Design International Limited have been central in advancing device engineering to support the accuracy and consistency of intranasal delivery. In this competitive arena, Emergent BioSolutions Inc. and GlaxoSmithKline PLC have leveraged their extensive expertise in vaccine development to explore the untapped potential of the nasal route for immunization strategies. Companies such as Hovione Limited and Impel Pharmaceuticals LLC. are also generating considerable interest with their focus on formulating stable and efficient intranasal products. Meanwhile, Indivior PLC and Intersect ENT by Medtronic plc continue to capitalize on their technological capabilities to push the boundaries of therapeutic administration.

In parallel, players like Intertek Group PLC and Johnson & Johnson Services, Inc. are ensuring that quality assurance and regulatory compliance are given utmost priority, a critical factor in achieving market success. Kindeva Drug Delivery L.P. and Merck & Co., Inc. further cement their market stance by actively pursuing research initiatives that address unmet clinical needs through innovative product designs. The strategic imperatives of Neurelis, Inc. and Novartis AG have positioned these companies as pivotal contributors to the development of next-generation intranasal solutions. Other influential names including OptiNose, Inc., Pfizer Inc., Recipharm AB, Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd. complete this rigorous competitive landscape, each playing a significant role in driving both incremental and breakthrough advancements.

This competitive mosaic illustrates not only the depth of research and development efforts but also the collaborative spirit that has emerged across the industry. The convergence of varied expertise has accelerated the pace of innovation and established a robust foundation for ongoing product development, ensuring that the market remains both dynamic and responsive to emerging therapeutic needs.

The report delves into recent significant developments in the Intranasal Drug & Vaccine Delivery Market, highlighting leading vendors and their innovative profiles. These include Altimmune, Inc., AptarGroup, Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Becton, Dickinson, and Company, Bharat Biotech Ltd., Boehringer Ingelheim International GmbH., Catalent, Inc, DCA Design International Limited, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Hovione Limited, Impel Pharmaceuticals LLC., Indivior PLC, Intersect ENT by Medtronic plc, Intertek Group PLC, Johnson & Johnson Services, Inc., Kindeva Drug Delivery L.P., Merck & Co., Inc., Neurelis, Inc., Novartis AG, OptiNose, Inc., Pfizer Inc., Recipharm AB., Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd.. Strategic, Actionable Recommendations for Market Leaders

In light of the current market trends and the deep segmentation insights gathered, industry leaders are provided with a suite of actionable recommendations that can be strategically deployed to optimize their competitive positioning. The first step involves a continued commitment to research and development, where investment in advanced formulation science and device technology remains paramount. Leaders should steer their innovation strategies toward integrative approaches that comprehensively address the full spectrum of patient needs while also streamlining production procedures.

Leveraging strategic partnerships and cross-industry collaborations can further enhance product pipelines and expedite market entry. Building robust networks with research institutions, regulatory bodies, and technology providers can lead to the early adoption of best practices, ensuring that new products are both effective and compliant with evolving standards. This collaborative approach not only mitigates risks associated with regulatory uncertainties but also acutely positions organizations to capitalize on emerging opportunities in niche therapeutic areas.

Emerging trends indicate that a focus on patient-centric product design is vital. Industry leaders are encouraged to invest in technologies and clinical research that provide granular insights into patient behaviors and treatment outcomes. Such investments can streamline the development of formulations that either target or effectively manage specific dosing requirements, thereby ensuring that the therapeutic efficacy is maximized. Additionally, optimizing the spectrum of device types-ranging from atomizers to nasal droppers and sprays-should now be considered a critical focus area. This refinement in the delivery mechanism can lead to significant improvements in patient adherence and overall drug performance.

Moreover, companies should undertake targeted market intelligence initiatives to monitor region-specific trends and competitive movements meticulously. Establishing agile research frameworks that are receptive to dynamic regulatory changes and are capable of quickly adapting to new market demands will be crucial for maintaining a competitive edge. Reinforcing investment in digital technologies to harness big data and predictive analytics can further refine market strategies and shape future investment pathways.

To encapsulate, it is essential for market leaders to adopt an integrated approach that leverages scientific innovation, strategic partnerships, and patient-centric insights. Implementing these recommendations will not only enhance operational efficiency but also secure a robust market position in the perpetually evolving landscape of intranasal drug and vaccine delivery.

Consolidated Summary and Forward-Looking Conclusion

In conclusion, the evolving landscape of intranasal drug and vaccine delivery offers a promising vista of opportunities and innovations that are redefining modern therapeutic practices. The convergence of transformational shifts, sophisticated segmentation insights, regional growth narratives, and competitive dynamics underscores a market that is both robust and responsive. As the industry continues to integrate novel technologies and embrace emergent research, stakeholders are witnessing unprecedented growth in clinical potential and patient accessibility.

This comprehensive analysis has outlined the critical trends that are shaping the future of intranasal delivery. A meticulous examination of segmentation based on drug type, formulation, devices, dosage, application, and end-user scenarios highlights the intricacy of the market and the diverse array of factors influencing its trajectory. Additionally, in-depth regional insights-from the well-established healthcare systems in the Americas and Europe, Middle East & Africa to the rapidly expanding opportunities in the Asia-Pacific-illustrate varying yet complementary growth dynamics.

Furthermore, an analysis of leading companies in the domain reveals strategic innovations that are central to driving market success. The interplay between cutting-edge research and real-world application is the cornerstone of market momentum, fortifying a base that is prepared to meet future challenges while capitalizing on emerging opportunities. Overall, this thorough evaluation confirms that the intranasal delivery market is not only poised for accelerated growth but also well-equipped to redefine the parameters of therapeutic innovation in the coming years.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising disease prevalence and syringe infection concerns propel growth in intranasal delivery systems
      • 5.1.1.2. Increasing popularity of self-administration of medications and non-invasive drug delivery routes
      • 5.1.1.3. Growing research and development activities focusing on innovations in intranasal vaccines
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative drug delivery methods and potential risk of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements related to intranasal drug delivery systems
      • 5.1.3.2. Substantial investments for R&D intranasal drug and vaccines delivery innovations
    • 5.1.4. Challenges
      • 5.1.4.1. Potential adverse reactions and side effects associated with intranasal drug administration
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing usage of non-opioid analgesics for chronic pain and long-term use owing to the lower risk of addiction and side effects
    • 5.2.2. Formulation Type: Innovative solutions and emerging applications in intranasal drug & vaccine delivery
    • 5.2.3. Device Type: Rising demand for atomizers owing to precision and efficacy in emergency treatments
    • 5.2.4. Dosage: Growing preference for multi-dose formats in large-scale immunization programs and chronic treatment protocols owing to cost-effectiveness and material efficiency
    • 5.2.5. Application: Rising preference for intranasal drug & vaccine delivery in allergy treatment to administer corticosteroids and antihistamines
    • 5.2.6. End-User: Expanding utilization of intranasal drug & vaccine delivery in homecare setups owing to better convenience and privacy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Intranasal Drug & Vaccine Delivery Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Analgesics
    • 6.2.1. Non-opioids
    • 6.2.2. Opioids
  • 6.3. Antihistamines
  • 6.4. Steroids
  • 6.5. Vaccines
    • 6.5.1. Inactivated Vaccines
    • 6.5.2. Live Attenuated Vaccines
    • 6.5.3. mRNA-based Vaccine

7. Intranasal Drug & Vaccine Delivery Market, by Formulation Type

  • 7.1. Introduction
  • 7.2. Gel Formulations
  • 7.3. Liquid Formulations
  • 7.4. Powder Formulations

8. Intranasal Drug & Vaccine Delivery Market, by Device Type

  • 8.1. Introduction
  • 8.2. Atomizer
  • 8.3. Nasal Dropper
  • 8.4. Nasal Spray

9. Intranasal Drug & Vaccine Delivery Market, by Dosage

  • 9.1. Introduction
  • 9.2. Multi-dose
  • 9.3. Unit-dose

10. Intranasal Drug & Vaccine Delivery Market, by Application

  • 10.1. Introduction
  • 10.2. Allergy Treatment
  • 10.3. Hormone Replacement
  • 10.4. Neurological Conditions
  • 10.5. Pain Management
  • 10.6. Psychiatric Disorders
  • 10.7. Therapeutic Drug Delivery

11. Intranasal Drug & Vaccine Delivery Market, by End-User

  • 11.1. Introduction
  • 11.2. Homecare
  • 11.3. Hospitals & Clinics
  • 11.4. Research & Academic Institution

12. Americas Intranasal Drug & Vaccine Delivery Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Intranasal Drug & Vaccine Delivery Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Intranasal Drug & Vaccine Delivery Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Orexo and Abera collaborate to advance intranasal powder vaccine development
    • 15.3.2. AuraVax Therapeutics secures a research contract from BARDA to investigate NanoSTING platform
    • 15.3.3. Aptar Pharma's strategic acquisition of SipNose enhances innovation in intranasal drug delivery systems
    • 15.3.4. FDA approval for at-home FluMist nasal spray offers needle-free solution to boost flu vaccination rates
    • 15.3.5. Rokote Laboratories partners with 3PBIOVIAN to advance intranasal COVID-19 vaccine manufacturing for clinical trials
    • 15.3.6. CastleVax secures USD 34 million funding to propel innovative intranasal COVID-19 vaccine into advanced trials
    • 15.3.7. BARDA invests USD 500 million in next-generation intranasal and oral COVID-19 vaccines
    • 15.3.8. Merck Animal Health transforms intranasal vaccination with innovative CleanVax nozzles and shields for enhanced hygiene and comfort
    • 15.3.9. Strategic collaboration to innovate nasal drug delivery with soft mist technology
    • 15.3.10. Kindeva expands intranasal drug-delivery capabilities with Summit Biosciences acquisition
    • 15.3.11. Oragenics acquisitions advance intranasal drug delivery for neurological treatments and market expansion
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. AstraZeneca PLC
    • 15.4.2. Pfizer Inc.
    • 15.4.3. Indivior PLC
    • 15.4.4. AptarGroup, Inc.

Companies Mentioned

  • 1. Altimmune, Inc.
  • 2. AptarGroup, Inc.
  • 3. AstraZeneca PLC
  • 4. Bausch Health Companies Inc.
  • 5. Bayer AG
  • 6. Becton, Dickinson, and Company
  • 7. Bharat Biotech Ltd.
  • 8. Boehringer Ingelheim International GmbH.
  • 9. Catalent, Inc
  • 10. DCA Design International Limited
  • 11. Emergent BioSolutions Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Hovione Limited
  • 14. Impel Pharmaceuticals LLC.
  • 15. Indivior PLC
  • 16. Intersect ENT by Medtronic plc
  • 17. Intertek Group PLC
  • 18. Johnson & Johnson Services, Inc.
  • 19. Kindeva Drug Delivery L.P.
  • 20. Merck & Co., Inc.
  • 21. Neurelis, Inc.
  • 22. Novartis AG
  • 23. OptiNose, Inc.
  • 24. Pfizer Inc.
  • 25. Recipharm AB.
  • 26. Sanofi S.A.
  • 27. Teleflex Incorporated
  • 28. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET MULTI-CURRENCY
  • FIGURE 2. INTRANASAL DRUG & VACCINE DELIVERY MARKET MULTI-LANGUAGE
  • FIGURE 3. INTRANASAL DRUG & VACCINE DELIVERY MARKET RESEARCH PROCESS
  • FIGURE 4. INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INTRANASAL DRUG & VACCINE DELIVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA INTRANASAL D